Drug Interaction Between Febuxostat and Thiopurine Antimetabolites: A Review of the FDA Adverse Event Reporting System and Medical Literature-Reference-Cited by-同舟云学术

Drug Interaction Between Febuxostat and Thiopurine Antimetabolites: A Review of the FDA Adverse Event Reporting System and Medical Literature

Published:2020-01-20 Issue:2 Volume:40 Page:125-132
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Logan Jill K.¹^ORCID,Wickramaratne Senarath Yapa Shalini²,Harinstein Lisa¹,Saluja Bhawana²,Muñoz Monica¹^ORCID,Sahajwalla Chandrahas²,Neuner Rosemarie³,Seymour Sally³

Affiliation:

1. Division of Pharmacovigilance Office of Surveillance and Epidemiology Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland

2. Division of Clinical Pharmacology Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland

3. Division of Pulmonary, Allergy, and Rheumatology Products Office of Drug Evaluation Office of New Drugs Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/phar.2362

Reference18 articles.

1. Febuxostat: A selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout

2. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007–2016

3. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase

4. U.S. Food and Drug Administration.Drugs@FDA: FDA Approved Drug Products. All Approvals. August 1966. Available fromhttps://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process&rptName=0&reportSelectMonth=8&reportSelectYear=1966&nav. Accessed January 24 2019.

5. Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat;Cureus;2023-10-07

2. Commensal bacteria promote azathioprine therapy failure in inflammatory bowel disease via decreasing 6-mercaptopurine bioavailability;Cell Reports Medicine;2023-08

3. Uric acid metabolism promotes apoptosis against Bombyx mori nucleopolyhedrovirus in silkworm, Bombyx mori;Insect Molecular Biology;2023-05-20

4. Treatment of Gout;A Clinician's Pearls & Myths in Rheumatology;2023

5. A Mobile App Leveraging Citizenship Engagement to Perform Anonymized Longitudinal Studies in the Context of COVID-19 Adverse Drug Reaction Monitoring: Development and Usability Study;JMIR Human Factors;2022-11-04